HLA-A*1101 & B2M & EBV (AVFDRKSDAK) Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Alintegimod | 7HP349; 7-HP-349; 7HP-349 | Phase 2 Clinical | 7 Hills Pharma LLC | Kidney Neoplasms; Liver Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Neoplasms; Skin Neoplasms; Mesothelioma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lifitegrast | SHP-606; SAR-1119; SAR-1118; OJL-332; SPD-606 | Approved | Shire Development Llc | Xiidra | United States | Dry Eye Syndromes | Bausch And Lomb Inc | 2016-07-11 | Keratoconjunctivitis Sicca; Graft vs Host Disease; Dry Eye Syndromes; Diabetic macular oedema; Conjunctivitis, Allergic; Xerophthalmia | Details |